Treatment algorithms based on tumor molecular profiling: The essence of precision medicine trials

Archive ouverte

Tourneau, Christophe Le | Kamal, Maud | Tsimberidou, Apostolia M. | Bedard, Philippe L. | Pierron, Gäelle L. | Callens, Celine | Rouleau, Étienne L. | Vincent-Salomon, Anne | Servant, Nicolas | Alt, Marie | Rouzier, Roman | Paoletti, Xavier | Delattre, Olivier O. | Bièche, Ivan

Edité par CCSD ; Oxford University Press (OUP) -

International audience. With the advent of high-throughput molecular technologies, several precision medicine (PM) studies are currently ongoing that include molecular screening programs and PM clinical trials. Molecular profiling programs establish the molecular profile of patients' tumors with the aim to guide therapy based on identified molecular alterations. The aim of prospective PM clinical trials is to assess the clinical utility of tumor molecular profiling and to determine whether treatment selection based on molecular alterations produces superior outcomes compared with unselected treatment. These trials use treatment algorithms to assign patients to specific targeted therapies based on tumor molecular alterations. These algorithms should be governed by fixed rules to ensure standardization and reproducibility. Here, we summarize key molecular, biological, and technical criteria that, in our view, should be addressed when establishing treatment algorithms based on tumor molecular profiling for PM trials.

Consulter en ligne

Suggestions

Du même auteur

Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis

Archive ouverte | Wassef, Michel Adam | CCSD

International audience. Alterations of chromatin modifiers are frequent in cancer, but their functional consequences often remain unclear. Focusing on the Polycomb protein EZH2 that deposits the H3K27me3 (trimethyla...

Non-invasive multi-cancer diagnosis using DNA hypomethylation of LINE-1 retrotransposons

Archive ouverte | Michel, Marc | CCSD

The detection of circulating tumor DNA, which allows non-invasive tumor molecular profiling and disease follow-up, promises optimal and individualized management of patients with cancer. However, detecting small fractions of tumor...

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Archive ouverte | Le Tourneau, Christophe | CCSD

International audience. Background: Molecularly targeted agents have been reported to have anti-tumour activity for patients whose tumours harbour the matching molecular alteration. These results have led to increas...

Chargement des enrichissements...